Study of Safety and Efficacy of RGT-61159 in Adults with Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

PHASE1RecruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

August 19, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2027

Conditions
Adenoid Cystic CarcinomaColorectal Cancer
Interventions
DRUG

RGT-61159

Oral MYB inhibitor

Trial Locations (10)

10016

RECRUITING

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

22031

RECRUITING

Next Oncology VA, Fairfax

48109

RECRUITING

University of Michigan, Ann Arbor

63110

RECRUITING

Washington University School of Medicine, St Louis

77030

RECRUITING

MD Anderson Cancer Center, Houston

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

K1H 8L6

RECRUITING

Ottawa Hospital Cancer Centre, Ottawa

M5G 2M9

RECRUITING

Princess Margaret Cancer Center, Toronto

All Listed Sponsors
lead

Rgenta Therapeutics Inc

INDUSTRY